Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 6
2013 2
2014 5
2015 3
2016 3
2017 2
2018 2
2019 6
2020 6
2021 5
2022 5
2023 10
2024 7
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, Zhao M, Barbour S, Jardine MJ, Reich HN, Cattran D, Glassock R, Levin A, Wheeler DC, Woodward M, Billot L, Stepien S, Rogers K, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Zhang H, Perkovic V; TESTING Study Group. Lv J, et al. JAMA. 2022 May 17;327(19):1888-1898. doi: 10.1001/jama.2022.5368. JAMA. 2022. PMID: 35579642 Free PMC article. Clinical Trial.
The Significance of Hematuria in Podocytopathies.
Marchel D, Trachtman H, Larkina M, Helmuth M, Lai Yee JY, Fermin D, Bomback AS, Canetta PA, Gipson DS, Mottl AK, Parekh RS, Saha MK, Sampson MG, Lafayette RA, Mariani LH; Nephrotic Syndrome Study Network (NEPTUNE) and Cure Glomerulonephropathy (CureGN). Marchel D, et al. Clin J Am Soc Nephrol. 2024 Jan 1;19(1):56-66. doi: 10.2215/CJN.0000000000000309. Epub 2023 Sep 21. Clin J Am Soc Nephrol. 2024. PMID: 37733352 Free PMC article.
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Barratt J, et al. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. Kidney Int. 2023. PMID: 36270561 Free article. Clinical Trial.
Proteinuria as an End Point in Clinical Trials of Focal Segmental Glomerulosclerosis.
Mariani LH, Trachtman H, Thompson A, Gillespie BS, Denburg M, Diva U, Geetha D, Greasley PJ, Hladunewich MA, Huizinga RB, Inrig JK, Komers R, Laurin LP, Little DJ, Nachman PH, Smith KA, Walsh L, Gibson KL. Mariani LH, et al. Among authors: laurin lp. Am J Kidney Dis. 2025 May;85(5):610-617. doi: 10.1053/j.ajkd.2024.08.011. Epub 2024 Oct 23. Am J Kidney Dis. 2025. PMID: 39455047 Free PMC article. Review.
Proteinuria Trajectory and Disease Progression in Children and Adults with IgA Nephropathy/Vasculitis.
Glenn DA, Carver AW, Helmuth ME, Smith AR, Lafayette RA, Ravipati P, Oliverio AL, Rizk DV, Novak J, Lugani F, Bartosh SM, Mucha K, Kiryluk K, Saha MK, Nast CC, Hou J, Biederman LE, Messias N, Rosenberg AZ, Reich HN, Canetta PA, Nachman PH, Nester C, Bou-Matar R, Wadhwani S, Mariani LH, Khalid M; CureGN IgA Working Group. Glenn DA, et al. Clin J Am Soc Nephrol. 2025 Apr 10;20(7):978-992. doi: 10.2215/CJN.0000000707. Clin J Am Soc Nephrol. 2025. PMID: 40208688
Family History in the Context of CKD.
Zanoni F, Marasa M, Carlassara L, Verbitsky M, Khan A, Wang C, Bundy JD, Canetta PA, Bomback AS, Parsa A, Feldman HI, Gharavi AG, Kiryluk K; CRIC Study Investigators and the CureGN Study. Zanoni F, et al. J Am Soc Nephrol. 2025 Mar 11;36(8):1561-1571. doi: 10.1681/ASN.0000000653. J Am Soc Nephrol. 2025. PMID: 40067412
Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial.
Walsh M, Collister D, Gallagher M, Mark PB, de Zoysa JR, Tyrwhitt J, Tennankore K, Reis G, Xavier D, Liu WJ, Zuo L, Wang AY, Félix C, Sola L, Arici M, Villanueva R, Jha V, Précoma D, Rabbat CG, Alavudeen SS, Faruqui AR, López-Flecher M, Pyne L, Wald R, Yuan F, Balasubramanian K, Lee SF, Kuptsova A, Christou C, Devereaux PJ; ACHIEVE Investigators. Walsh M, et al. Lancet. 2025 Aug 16;406(10504):695-704. doi: 10.1016/S0140-6736(25)01198-5. Lancet. 2025. PMID: 40818850 Clinical Trial.
62 results